JPS6035263A - 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 - Google Patents
不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬Info
- Publication number
- JPS6035263A JPS6035263A JP58144201A JP14420183A JPS6035263A JP S6035263 A JPS6035263 A JP S6035263A JP 58144201 A JP58144201 A JP 58144201A JP 14420183 A JP14420183 A JP 14420183A JP S6035263 A JPS6035263 A JP S6035263A
- Authority
- JP
- Japan
- Prior art keywords
- carrier
- substance
- immobilized
- solution
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 39
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 55
- 230000006641 stabilisation Effects 0.000 title claims description 6
- 238000011105 stabilization Methods 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title description 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims abstract description 12
- 102000036639 antigens Human genes 0.000 claims abstract description 12
- 108091007433 antigens Proteins 0.000 claims abstract description 12
- 235000000346 sugar Nutrition 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 238000007654 immersion Methods 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 51
- 239000011521 glass Substances 0.000 claims description 26
- -1 polypropylene Polymers 0.000 claims description 16
- 239000004793 Polystyrene Substances 0.000 claims description 15
- 229920002223 polystyrene Polymers 0.000 claims description 15
- 230000000087 stabilizing effect Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 150000005846 sugar alcohols Polymers 0.000 claims description 13
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 12
- 239000004800 polyvinyl chloride Substances 0.000 claims description 12
- 238000003127 radioimmunoassay Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 229920001059 synthetic polymer Polymers 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 150000008163 sugars Chemical class 0.000 claims description 6
- 229910044991 metal oxide Inorganic materials 0.000 claims description 5
- 150000004706 metal oxides Chemical class 0.000 claims description 5
- 238000003018 immunoassay Methods 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 56
- 239000012460 protein solution Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 238000001179 sorption measurement Methods 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000010981 drying operation Methods 0.000 abstract 1
- 239000011324 bead Substances 0.000 description 42
- 239000008363 phosphate buffer Substances 0.000 description 34
- 150000001720 carbohydrates Chemical class 0.000 description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 238000005259 measurement Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 229940125396 insulin Drugs 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 229940098773 bovine serum albumin Drugs 0.000 description 15
- 239000007853 buffer solution Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 239000008213 purified water Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 108010071390 Serum Albumin Proteins 0.000 description 7
- 102000007562 Serum Albumin Human genes 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 230000002494 anti-cea effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000007575 Calluna vulgaris Nutrition 0.000 description 2
- 241001669680 Dormitator maculatus Species 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000005373 porous glass Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 101100009425 Danio rerio dexi gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101100009427 Mus musculus Dexi gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- CWAFVXWRGIEBPL-UHFFFAOYSA-N ethoxysilane Chemical compound CCO[SiH3] CWAFVXWRGIEBPL-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58144201A JPS6035263A (ja) | 1983-08-05 | 1983-08-05 | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 |
DE8484305286T DE3477844D1 (en) | 1983-08-05 | 1984-08-03 | Method for stabilizing immunologically active substances immobilized on an insoluble carrier and their use in the preparation of reagents for measuring physiologically active substances |
EP84305286A EP0140489B1 (en) | 1983-08-05 | 1984-08-03 | Method for stabilizing immunologically active substances immobilized on an insoluble carrier and their use in the preparation of reagents for measuring physiologically active substances |
AT84305286T ATE42410T1 (de) | 1983-08-05 | 1984-08-03 | Verfahren zur stabilisierung von, auf einem unloeslichen traeger, immobilisierten substanzen mit immunologischer wirksamkeit und ihre verwendung in der herstellung von reagenzien zur messung von substanzen mit physiologischer wirksamkeit. |
US07/659,476 US5273908A (en) | 1983-08-05 | 1991-02-25 | Stabilizing method for immuno active substances immobilized on insoluble carrier and its use in preparation of reagent for measuring physiologically active substances |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58144201A JPS6035263A (ja) | 1983-08-05 | 1983-08-05 | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6035263A true JPS6035263A (ja) | 1985-02-23 |
JPH0541946B2 JPH0541946B2 (en, 2012) | 1993-06-25 |
Family
ID=15356567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58144201A Granted JPS6035263A (ja) | 1983-08-05 | 1983-08-05 | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0140489B1 (en, 2012) |
JP (1) | JPS6035263A (en, 2012) |
AT (1) | ATE42410T1 (en, 2012) |
DE (1) | DE3477844D1 (en, 2012) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61241665A (ja) * | 1985-04-18 | 1986-10-27 | Toyobo Co Ltd | 安定化された固相試薬 |
JPS6234059A (ja) * | 1985-08-07 | 1987-02-14 | Sankyo Co Ltd | 固相化試薬の安定化剤 |
JPH02161357A (ja) * | 1988-12-15 | 1990-06-21 | Tosoh Corp | 免疫測定用材料の安定化方法 |
JPH02173568A (ja) * | 1988-11-09 | 1990-07-05 | Biotrack Inc | ラテックス試薬を安定化し、そして溶解するための方法及び組成物 |
JP2010014685A (ja) * | 2008-07-04 | 2010-01-21 | Bio Matrix Research Inc | タンパク質安定化溶液 |
JP2010230660A (ja) * | 2009-03-06 | 2010-10-14 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体定量用標準品 |
JP2017181492A (ja) * | 2016-03-24 | 2017-10-05 | 三洋化成工業株式会社 | 粒子組成物、免疫測定用試薬及び免疫測定方法 |
WO2018194134A1 (ja) * | 2017-04-20 | 2018-10-25 | 株式会社シノテスト | 抗ペリオスチン抗体固定化担体、ペリオスチン測定試薬、及び抗ペリオスチン抗体固定化担体における抗体の安定化方法 |
JP2021071476A (ja) * | 2019-10-29 | 2021-05-06 | 三洋化成工業株式会社 | 免疫測定用試薬、免疫測定用キット及び免疫測定方法 |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2187191B (en) * | 1984-01-30 | 1989-11-01 | Quadrant Bioresources Ltd | Protection of proteins and the like |
GB8500698D0 (en) * | 1985-01-11 | 1985-02-13 | Unilever Plc | Preparation of reagents |
DE229810T1 (de) * | 1985-07-09 | 1987-11-05 | Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire | Beschuetzung von proteinen und aehnlichem. |
JPS62170850A (ja) * | 1986-01-23 | 1987-07-27 | Wako Pure Chem Ind Ltd | 免疫化学的測定法 |
US5514602A (en) * | 1986-06-09 | 1996-05-07 | Ortho Diagnostic Systems, Inc. | Method of producing a metal sol reagent containing colloidal metal particles |
EP1248112A3 (en) | 1987-04-27 | 2004-08-25 | Inverness Medical Switzerland GmbH | Immunochromatographic specific binding assay device |
FR2616915B1 (fr) * | 1987-06-16 | 1989-09-29 | Ire Medgenix Sa | Solution d'une substance de nature polypeptidique, et utilisation pour des dosages immunologiques |
GB8716826D0 (en) * | 1987-07-16 | 1987-08-19 | Tills D | Protection of proteinaceous reagents |
GB8801338D0 (en) * | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
US5262296A (en) * | 1988-03-30 | 1993-11-16 | Toray Industries, Inc. | Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition |
DE3811659C1 (en, 2012) * | 1988-04-07 | 1989-11-16 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De | |
US5077198A (en) * | 1988-04-14 | 1991-12-31 | Eastman Kodak Company | Diagnostic kit and method for rapid detection of antibodies |
US5759774A (en) * | 1988-05-18 | 1998-06-02 | Cobe Laboratories, Inc. | Method of detecting circulating antibody types using dried or lyophilized cells |
US5030560A (en) * | 1988-11-04 | 1991-07-09 | Immucor, Inc. | Method for drying mammalian cells for use in solid phase immunoassays and articles incorporating same |
US5192663A (en) * | 1988-11-04 | 1993-03-09 | Immucor, Inc. | Article having an organic dye and a monolayer of dried mammalian cells and a method for utilizing the article |
US5102788A (en) * | 1988-11-21 | 1992-04-07 | Hygeia Sciences, Inc. | Immunoassay including lyophilized reactant mixture |
FR2645967B1 (fr) * | 1989-04-12 | 1994-04-01 | Diagnostica Stago | Procede d'adsorption d'un materiel immunologique, utilisation dans le domaine des reactions antigene/anticorps |
USRE38385E1 (en) | 1989-02-16 | 2004-01-13 | Nektar Therapeutics | Storage of materials |
GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
DE3919393A1 (de) * | 1989-06-14 | 1990-12-20 | Hoechst Ag | Verfahren zur stabilisierung von auf festphasen immobilisierten biologisch aktiven substanzen |
US6143508A (en) * | 1989-06-29 | 2000-11-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Device and process for cell capture and recovery |
CA1340565C (en) | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
AU633981B2 (en) * | 1989-10-12 | 1993-02-11 | Takeda Chemical Industries Ltd. | Antigen-sensitized bead and use thereof |
US5252496A (en) * | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
CA2053299A1 (en) * | 1990-02-28 | 1991-08-29 | Marvin A. Motsenbocker | Immunoassay |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
ES2147185T3 (es) * | 1991-10-11 | 2000-09-01 | Abbott Lab | Composicion de reactivo en dosis unitaria para ensayos por union especifica. |
JP3167415B2 (ja) * | 1992-04-30 | 2001-05-21 | オリンパス光学工業株式会社 | 固相免疫検査における抗原細胞の保存方法 |
GB9211176D0 (en) * | 1992-05-27 | 1992-07-08 | Central Blood Lab Authority | Assay |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
CZ286632B6 (cs) | 1992-09-29 | 2000-05-17 | Inhale Therapeutic Systems | Farmaceutický prostředek |
AU689217B2 (en) | 1994-03-07 | 1998-03-26 | Novartis Ag | Methods and compositions for pulmonary delivery of insulin |
BE1008221A3 (fr) * | 1994-03-28 | 1996-02-20 | Anda Biolog Sa | Support solide fixant au moins un composant a activite biologique comprenant un site reactionnel, stabilise et procede pour son obtention. |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
US6979576B1 (en) | 1997-07-25 | 2005-12-27 | Shu-Ching Cheng | Methods of use of one step immunochromatographic device for Streptococcus A antigen |
AU7590198A (en) * | 1997-06-10 | 1998-12-30 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
IL121116A (en) * | 1997-06-19 | 2000-12-06 | Savyon Diagnostics Ltd | Stabilization of polypeptides for use in immunoassay procedures |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
FR2777355B1 (fr) * | 1998-04-10 | 2000-05-12 | Bio Merieux | Procede de fixation d'une molecule biologique sur la surface d'un support constitue de silice ou d'oxyde metallique |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7442388B2 (en) | 2000-05-10 | 2008-10-28 | Weers Jeffry G | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
SI1458360T1 (sl) | 2001-12-19 | 2011-08-31 | Novartis Ag | Pulmonalno dajanje aminoglikozidov |
US6927062B2 (en) | 2002-11-25 | 2005-08-09 | Agdia, Inc. | Controls and standards for assays and method for manufacture thereof |
US20080050737A1 (en) * | 2006-05-23 | 2008-02-28 | Boaz Arieli | Ambient Temperature Stable Kits for Molecular Diagnostics |
JP5349838B2 (ja) | 2007-11-30 | 2013-11-20 | 和光純薬工業株式会社 | smallRNAの取得用担体、取得方法及び取得用試薬 |
EP2230515B1 (en) | 2009-03-16 | 2014-12-17 | Agilent Technologies, Inc. | Passivation of surfaces after ligand coupling |
KR102582192B1 (ko) | 2014-12-05 | 2023-09-25 | 후지필름 가부시키가이샤 | Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트 |
JP7461382B2 (ja) | 2020-01-15 | 2024-04-03 | 富士フイルム株式会社 | 抗炎症剤、及び抗炎症作用を有する細胞外小胞の製造方法 |
JP7425092B2 (ja) | 2020-01-15 | 2024-01-30 | 富士フイルム株式会社 | 抗線維化剤、及び抗線維化作用を有する細胞外小胞の製造方法 |
JP7538150B2 (ja) | 2020-01-15 | 2024-08-21 | 富士フイルム株式会社 | 血管新生剤、及び血管新生作用を有する細胞外小胞の製造方法 |
KR20250110928A (ko) | 2022-12-28 | 2025-07-21 | 후지필름 가부시키가이샤 | 다공질 담체, 세포 외 소포를 취득하는 방법, 세포 외 소포를 제조하는 방법, 및, 키트 |
WO2025012398A1 (en) | 2023-07-11 | 2025-01-16 | Olink Proteomics Ab | Dried reagents |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4921052A (en, 2012) * | 1972-06-16 | 1974-02-25 | ||
JPS5423118A (en) * | 1977-07-25 | 1979-02-21 | Kitasato Inst | Vaccine for bibrio disease of bred fish |
JPS57103649A (en) * | 1980-12-18 | 1982-06-28 | Asahi Chemical Ind | Sterilized gamma-globulin fixing column |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2016687B (en) * | 1978-03-20 | 1982-09-08 | Abbott Lab | Sugar coated reagents for solid phase immunoassay |
JPH0235944B2 (en, 2012) * | 1980-06-20 | 1990-08-14 | Unilever Nv | |
AR231590A1 (es) * | 1981-04-29 | 1984-12-28 | Ciba Geigy Ag | Dispositivo de analisis inmunologico y procedimiento para obtenerlo |
JPS57182168A (en) * | 1981-05-02 | 1982-11-09 | Mitsubishi Chem Ind Ltd | Immunochemical reagent |
GB2124231B (en) * | 1982-05-24 | 1985-10-02 | Corning Glass Works | Solid phase reagent for immunoassay |
-
1983
- 1983-08-05 JP JP58144201A patent/JPS6035263A/ja active Granted
-
1984
- 1984-08-03 EP EP84305286A patent/EP0140489B1/en not_active Expired
- 1984-08-03 AT AT84305286T patent/ATE42410T1/de not_active IP Right Cessation
- 1984-08-03 DE DE8484305286T patent/DE3477844D1/de not_active Expired
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4921052A (en, 2012) * | 1972-06-16 | 1974-02-25 | ||
JPS5423118A (en) * | 1977-07-25 | 1979-02-21 | Kitasato Inst | Vaccine for bibrio disease of bred fish |
JPS57103649A (en) * | 1980-12-18 | 1982-06-28 | Asahi Chemical Ind | Sterilized gamma-globulin fixing column |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61241665A (ja) * | 1985-04-18 | 1986-10-27 | Toyobo Co Ltd | 安定化された固相試薬 |
JPS6234059A (ja) * | 1985-08-07 | 1987-02-14 | Sankyo Co Ltd | 固相化試薬の安定化剤 |
JPH02173568A (ja) * | 1988-11-09 | 1990-07-05 | Biotrack Inc | ラテックス試薬を安定化し、そして溶解するための方法及び組成物 |
JPH02161357A (ja) * | 1988-12-15 | 1990-06-21 | Tosoh Corp | 免疫測定用材料の安定化方法 |
JP2010014685A (ja) * | 2008-07-04 | 2010-01-21 | Bio Matrix Research Inc | タンパク質安定化溶液 |
JP2010230660A (ja) * | 2009-03-06 | 2010-10-14 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体定量用標準品 |
JP2017181492A (ja) * | 2016-03-24 | 2017-10-05 | 三洋化成工業株式会社 | 粒子組成物、免疫測定用試薬及び免疫測定方法 |
WO2018194134A1 (ja) * | 2017-04-20 | 2018-10-25 | 株式会社シノテスト | 抗ペリオスチン抗体固定化担体、ペリオスチン測定試薬、及び抗ペリオスチン抗体固定化担体における抗体の安定化方法 |
JPWO2018194134A1 (ja) * | 2017-04-20 | 2020-02-27 | 株式会社シノテスト | 抗ペリオスチン抗体固定化担体、ペリオスチン測定試薬、及び抗ペリオスチン抗体固定化担体における抗体の安定化方法 |
JP2021071476A (ja) * | 2019-10-29 | 2021-05-06 | 三洋化成工業株式会社 | 免疫測定用試薬、免疫測定用キット及び免疫測定方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE42410T1 (de) | 1989-05-15 |
EP0140489A1 (en) | 1985-05-08 |
JPH0541946B2 (en, 2012) | 1993-06-25 |
EP0140489B1 (en) | 1989-04-19 |
DE3477844D1 (en) | 1989-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6035263A (ja) | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 | |
US3966897A (en) | Medium for use in bioassay and method of using same | |
US4639425A (en) | Heterogeneous immunoassay and reagent therefore | |
EP0303110A2 (en) | Immunodiagnostic device and method | |
CA1289875C (en) | Immunoassay test strip | |
IL45646A (en) | METHOD AND DEVICE FOR QUANTITATIVE DETERMINATION OF MATERIALS WITH LINKLY RELATIONSHIP | |
EP0185738A4 (en) | Immunoliposome assay - methods and products. | |
GB2085160A (en) | Measurement of free thyroxine or free 3,5,3'triiodothyronine in a liquid sample | |
JPS632348B2 (en, 2012) | ||
US4686181A (en) | Specific binding assay employing anti-G6PDH as label | |
JPS6071957A (ja) | 超音波処理により免疫反応を促進する方法 | |
EP0394398A1 (en) | NANOPARTICLES WITH BONDED ENZYME AND LIGAND FOR USE IN ANALYZES. | |
US4971904A (en) | Heterogeneous immunoassay | |
TW494238B (en) | Chromatographic test pieces and chromatographic assay | |
US4729961A (en) | Process for the detection and assay by erythroadsorption | |
JPS63277971A (ja) | マーカー上に金属粒子を析出させるための改良方法 | |
JPH11133023A (ja) | 尿試料を使用する免疫クロマトグラフィー検定の尿素の影響を減らすための配合物 | |
CN112255421A (zh) | 一种脂蛋白a检测试剂盒及检测方法 | |
Guesdon et al. | Solid phase enzyme immunoassays | |
CN111566081B (zh) | 一种双酰胺复合物及其制备方法和用途 | |
US5210020A (en) | Immunoassay utilizing alginate to enhance signal to noise ratio | |
US5273908A (en) | Stabilizing method for immuno active substances immobilized on insoluble carrier and its use in preparation of reagent for measuring physiologically active substances | |
US4467030A (en) | Determination of the thyroxine-binding index in serum | |
US5250443A (en) | Biological diagnostic assay system | |
JPH0566985B2 (en, 2012) |